Certara, Inc. (NASDAQ:CERT) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Certara, Inc. (NASDAQ:CERT - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $15.71.

CERT has been the subject of several research analyst reports. Barclays raised Certara from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $11.00 to $14.00 in a research report on Thursday, May 8th. JMP Securities reissued a "market perform" rating on shares of Certara in a research report on Tuesday, May 6th. Morgan Stanley initiated coverage on Certara in a research report on Thursday. They set an "equal weight" rating and a $16.00 price objective for the company. KeyCorp boosted their price objective on Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 16th. Finally, Robert W. Baird boosted their price objective on Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th.

Certara Stock Down 1.4%

Shares of NASDAQ:CERT traded down $0.16 on Wednesday, reaching $11.33. The company had a trading volume of 1,281,456 shares, compared to its average volume of 1,459,372. Certara has a twelve month low of $8.64 and a twelve month high of $16.93. The stock has a 50-day moving average price of $11.65 and a 200 day moving average price of $11.85. The stock has a market capitalization of $1.84 billion, a P/E ratio of -566.50 and a beta of 1.43. The company has a quick ratio of 2.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. Certara had a positive return on equity of 5.05% and a negative net margin of 0.67%. The company had revenue of $106.00 million during the quarter, compared to analysts' expectations of $104.44 million. During the same quarter in the previous year, the firm earned $0.10 earnings per share. The business's quarterly revenue was up 9.7% compared to the same quarter last year. On average, equities analysts expect that Certara will post 0.28 EPS for the current year.

Hedge Funds Weigh In On Certara

Large investors have recently added to or reduced their stakes in the company. Versant Capital Management Inc raised its holdings in Certara by 218.8% in the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock valued at $27,000 after acquiring an additional 1,866 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Certara in the 1st quarter valued at approximately $31,000. Wells Fargo & Company MN raised its holdings in Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after acquiring an additional 1,047 shares in the last quarter. AlphaQuest LLC acquired a new position in Certara in the 1st quarter valued at approximately $39,000. Finally, Johnson Financial Group Inc. acquired a new position in Certara in the 4th quarter valued at approximately $47,000. Institutional investors and hedge funds own 73.96% of the company's stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.